DRG Epidemiology's coverage of rheumatoid arthritic pain comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of rheumatoid arthritic pain for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology's rheumatoid arthritic pain forecast will answer the following questions:
Of all people diagnosed with rheumatoid arthritic pain, how many in each country across the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of rheumatoid arthritic pain over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following rheumatoid arthritic pain subpopulations:
Diagnosed prevalent cases by drug-treatment status
Diagnosed Prevalence of Rheumatoid Arthritic Pain per 1,000 Among Adults in 2020 and 2030ttttttttt
Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Rheumatoid Arthritic Pain over the Next Ten Years
Epidemiology Data
Methods
Diagnosed Prevalence
Percentage Drug-Treated
Reference Materials
Literature Review
Studies Included in the Analysis of Rheumatoid Arthritic Pain
Studies Excluded from the Analysis of Rheumatoid Arthritic Pain
Risk/Protective Factors
Risk/Protective Factors for Rheumatoid Arthritic Pain
Bibliography
Glossary
Aishwarya S. Ambat
Aishwarya S. Ambat, M.P.H., is an associate epidemiologist at Clarivate. She received her M.P.H. from the Manipal Academy of Higher Education in India and holds a bachelor’s degree in physiotherapy.
Alison Isherwood, M.Sc., M.Res., Ph.D.
Alison Isherwood, M.Sc., M.Res., Ph.D., is a senior director on the Epidemiology team at Clarivate. She specializes in female cancers, biomarker, and infectious disease epidemiology, particularly involving the impact of vaccination. She holds a B.Sc. in medical microbiology, a master’s degree in research in the life sciences (specializing in virology and parasitology), and an M.Sc. in epidemiology, all from the University of Edinburgh. She also holds a Ph.D. in molecular virology from the University of Reading in England.
